

Oral Evaluation for Adults with Diabetes

Measure Basic Information

Name and date of specifications used: Dental Quality Alliance (DQA) Adults with Diabetes – Oral Evaluation.

URL of Specifications:

https://www.ada.org/-/media/project/ada-organization/ada/ada-org/files/resources/research/dqa/dental-quality-measures/2023-measures/2023_dqa_diabetes_oral_evaluation.pdf

Measure Type:

HEDIS PQI Survey Other Specify: DQA

Measure Utility:

CCO Incentive State Quality CMS Adult Core Set CMS Child Core Set Other Specify:

Data Source: MMIS/DSSURS

Measurement Period: January 1, 2023 – December 31, 2023

Benchmark for OHA measurement year	2021	2022	2023
OED	17.3%	20.4%	26.4%
Source:	MY2020 CCO 25 th percentile	MY2020 CCO 75 th percentile	MY2021 CCO 90 th percentile

2023 Improvement Targets: Minnesota method with 1 percentage point floor.

Note on telehealth: This measure may be eligible for teledentistry. The intent of the measure is to ensure that members with diabetes had the touchpoint with the dental delivery system and had diagnoses and treatment planning. These activities as documented in the claims data by the dentist/ dental health provider is based on their clinical judgment. If the rendering provider documents a qualifying CDT code (D0120, D0150 or D0180) in the claims form, the visit should be counted in the measure, irrespective if the visit was virtual (Teledentistry) or in person. For further information please see [American Dental Association policy on teledentistry](#).

Changes in specifications from MY2022 to MY2023:

DQA follows NCQA HEDIS specifications for identifying members with diabetes. ~~OHA follows the HEDIS MY2023 specifications for the matching measurement year reporting~~ which includes the following updates:

- ~~• Added required exclusion for members who died anytime in the measurement year.~~
- Added a direct reference code for palliative care exclusion.
- Updated the Diabetes Medication List.

Member type: CCO A CCO B CCO G

Specify claims used in the calculation:

DOE	Only use claims from matching CCO that a member is enrolled with	Denied claims included
Denominator inclusion and exclusion	N ¹	Y
Numerator event	Y	Y

Measure Details

Data elements required denominator:

Unduplicated members age 18 and above as of December 31 of the measurement year with diabetes identified from claim/encounter data or pharmacy data. A member qualifies for the measure denominator if at least one of the following four criteria is met either during the measurement year or the year prior to the measurement year:

Claims/Encounter Data:

Members who met any of the following criteria during the measurement year or the year prior to the measurement year ~~(count services that occur over both years):~~

1. At least one acute inpatient encounter (Acute Inpatient Value Set) with a diagnosis of diabetes (Diabetes Value Set) **without** telehealth (Telehealth Modifier Value Set; Telehealth POS Value Set).
2. At least one acute inpatient discharge with a diagnosis of diabetes (Diabetes Value Set) on the discharge claim. To identify an acute inpatient discharge:
 - o Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
 - o Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
 - o Identify the discharge date for the stay.
3. At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), ED visits (ED Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim), on different dates of service, with a diagnosis of diabetes (Diabetes Value Set). Visit type need not be the same for the two encounters. To identify a nonacute inpatient discharge:
 - o Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
 - o Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
 - o Identify the discharge date for the stay

Only include nonacute inpatient encounters (Nonacute Inpatient Value Set) **without** telehealth (Telehealth Modifier Value Set; Telehealth POS Value Set).

¹ From the two-year period for identifying diabetes members in the denominator, all claims in OHA data warehouse are used regardless of the payer.

Pharmacy Data:

- Members who were dispensed insulin or hypoglycemics/ antihyperglycemics during the measurement year or the year prior to the measurement year (Diabetes Medications List).

Diabetes Medications List²

Description	Prescription		
Alpha-glucosidase inhibitors	• Acarbose	• Miglitol	
Amylin analogs	• Pramlintide		
Antidiabetic combinations	<ul style="list-style-type: none"> • Alogliptin-metformin • Alogliptin-pioglitazone • Canagliflozin-metformin • Dapagliflozin-metformin • Dapagliflozin-saxagliptin • Empagliflozin-linagliptin • Empagliflozin-linagliptin-metformin 	<ul style="list-style-type: none"> • Empagliflozin-metformin • Ertugliflozin-metformin • Ertugliflozin-sitagliptin • Glimepiride-pioglitazone • Glipizide-metformin • Glyburide-metformin 	<ul style="list-style-type: none"> • Linagliptin-metformin • Metformin-pioglitazone • Metformin-repaglinide • Metformin-rosiglitazone • Metformin-saxagliptin • Metformin-sitagliptin
Insulin	<ul style="list-style-type: none"> • Insulin aspart • Insulin aspart-insulin aspart protamine • Insulin degludec • Insulin degludec-liraglutide • Insulin detemir • Insulin glargine • Insulin glargine-lixisenatide 	<ul style="list-style-type: none"> • Insulin glulisine • Insulin isophane human • Insulin isophane-insulin regular • Insulin lispro • Insulin lispro-insulin lispro protamine • Insulin regular human • Insulin human inhaled 	
Meglitinides	• Nateglinide	• Repaglinide	
Glucagon-like peptide-1 (GLP1) agonists	<ul style="list-style-type: none"> • Albiglutide • Dulaglutide • Exenatide 	<ul style="list-style-type: none"> • Liraglutide (excluding Saxenda®) • Lixisenatide • Semaglutide 	
Sodium glucose cotransporter 2 (SGLT2) inhibitor	<ul style="list-style-type: none"> • Canagliflozin • Dapagliflozin (excluding Farxiga®) 	<ul style="list-style-type: none"> • Ertugliflozin • Empagliflozin 	
Sulfonylureas	<ul style="list-style-type: none"> • Chlorpropamide • Glimepiride 	<ul style="list-style-type: none"> • Glipizide • Glyburide 	<ul style="list-style-type: none"> • Tolazamide • Tolbutamide
Thiazolidinediones	• Pioglitazone	• Rosiglitazone	
Dipeptidyl peptidase-4 (DDP-4) inhibitors	<ul style="list-style-type: none"> • Alogliptin • Linagliptin 	<ul style="list-style-type: none"> • Saxagliptin • Sitagliptin 	

Note: Glucophage/metformin as a solo agent is not included because it is used to treat conditions other than diabetes; members with diabetes on these medications are identified through diagnosis codes only.

Required exclusions for denominator:

² HEDIS NDC lists are available at: <https://www.ncqa.org/hedis/measures/>

1. Members who did not have a diagnosis of diabetes (Diabetes Value Set), in any setting, during the measurement year or the year prior to the measurement year **and** who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid-induced diabetes (Diabetes Exclusions Value Set), in any setting, during the measurement year or the year prior to the measurement year³. In other words, this exclusion only applies to members who are identified in denominator solely through diabetes-related pharmacy claims but no medical visits with type I or type II diagnoses.
2. Members in hospice or using hospice services any time during the measurement year. Refer to *General Guideline 15: Members in Hospice*. These members are identified using HEDIS MY2023 Hospice Encounter Value Set and Hospice Intervention Value Set, with claims within the measurement year.
- ~~3. Members who died any time during the measurement year. Refer to HEDIS MY2023 General Guideline 16: Deceased Members.~~
- 4.3. Members receiving palliative care (Palliative Care Assessment Value Set; Palliative Care Encounter Value Set; Palliative Care Intervention Value Set; ICD-10-CM code Z51.5) any time during the measurement year.
- 5.4. Medicare members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
 - a. Enrolled in an Institutional SNP (I-SNP) any time during the measurement year.
 - b. Living long-term in an institution any time during the measurement year as identified by the LTI flag in the Monthly Membership Detail Data File. Use the run date of the file to determine if a member had an LTI flag during the measurement year⁴.
- 6.5. Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty **and** advanced illness. Members must meet **BOTH** of the following frailty and advanced illness criteria to be excluded:
 - a. At least ~~two~~one indications of frailty (Frailty Device Value Set; Frailty Diagnosis Value Set; Frailty Encounter Value Set; Frailty Symptom Value Set) with different dates of service during the measurement year.
AND
 - b. Any of the following during the measurement year or the year prior to the measurement year (count services that occur over both years):
 - i. At least two outpatient visits (Outpatient Value Set), observation visits (Observation Value Set), ED visits (ED Value Set), telephone visits (Telephone Visits Value Set), e-visits or virtual check-ins (Online Assessments Value Set), nonacute inpatient encounters (Nonacute Inpatient Value Set) or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim) on different dates of service, with an advanced illness diagnosis (Advanced Illness Value Set). Visit type need not be the same for the two visits. To identify a nonacute inpatient discharge:
 1. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
 2. Confirm the stay was for nonacute care based on the presence of a nonacute code (Nonacute Inpatient Stay Value Set) on the claim.
 - a. Identify the discharge date for the stay.

³ Note this is originally an optional exclusion for the HEDIS Comprehensive Diabetes Care measure, and DQA adopts it as a required denominator exclusion.

⁴ The I-SNP exclusion makes use of the Territorial Benefit Query (TBQ) files from CMS to identify the Contract Number and Plan Number of Oregon Medicaid recipients who are dual eligible in Medicare Advantage plans. Dual eligible Medicaid recipients who were enrolled in Medicare Special Needs Plans and institutionalized at any time during the measurement year are excluded.

- b. At least one acute inpatient encounter (Acute Inpatient Value Set) with an advanced illness diagnosis (Advanced Illness Value Set).
- c. At least one acute inpatient discharge with an advanced illness diagnosis (Advanced Illness Value Set) on the discharge claim. To identify an acute inpatient discharge:
 - i. Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
 - ii. Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
 - iii. Identify the discharge date for the stay.
- d. A dispensed dementia medication (Dementia Medications List).

Dementia Medications List⁶

Description	Prescription
Cholinesterase inhibitors	• Donepezil • Galantamine • Rivastigmine
Miscellaneous central nervous system agents	• Memantine
Dementia combinations	• Donepezil-memantine

Deviations from cited specifications for denominator:

DQA requires exclusion for members who are dual eligible for Medicaid and Medicare, but OHA does not adopt this exclusion. Including dual enrollees is a common practice for all CCO metrics. OHA excludes I-SNP and LTI members to be consistent with other CCO metrics.

Continuous enrollment criteria: The measurement year.

Allowable gaps in enrollment:

No more than one gap in enrollment of up to 45 days during the measurement year.

Anchor Date (if applicable): None⁶.

Data elements required numerator:

Number of unduplicated members in the denominator who received a comprehensive, periodic or periodontal oral evaluation in the measurement year, identified by any of the following CDT codes: D0120, D0150, or D0180.

Required exclusions for numerator: None.

Deviations from cited specifications for numerator: None.

⁵ HEDIS NDC lists are available at: <https://www.ncqa.org/hedis/measures/>

⁶ Note while HEDIS Diabetes-related measures have an anchor date on December 31st of the measurement year; OHA adopts DQA specifications which does not require an anchor date.

Version Control

The specifications are updated on August 17, 2023 to realign methodology with DQA 2023 Specifications instead of NCQA 2023 Specifications.